CDK6 and glioblastoma: However, GBM-N019-targeted mTOR/CDK6/STAT3 signature, supported by a wealth of literature, contributes to tumor progressions, stemness, distant metastasis, and regulation of immune checkpoint blockade therapy outcome [23,57,74,87,91].